SUMMIT DETAILS - 2021

Science, Regulation and Public Health

Smoking is the biggest single cause of preventable death in the developed world with almost 1 billion users worldwide. The devastating effect of long-term smoking cannot be underestimated, with approximately half of all lifetime smokers dying from smoking related diseases and many more suffering a compromised quality of life.  Despite decades of successful tobacco control efforts, we are still a long way from ending the smoking epidemic. The emergence of e-cigarettes has created one of the most controversial and contentious public health issues of a generation, with divisions appearing within longstanding professional alliances in both Tobacco Control and Public Health communities, despite a continued shared goal of protecting public health and ending the smoking epidemic.

The E-Cigarette Summit provides a  neutral platform to explore the available peer reviewed evidence and debate the issues that are dividing scientists, health professionals and policy makers alike. So, are-cigarettes a valuable harm reduction strategy or a tacit U-turn on decades of effective tobacco control efforts? Whichever side of the debate you fall on, this is likely to be one of the most significant public health issues for a generation.

The Summit takes place on US Eastern Time and all registered participants will be able to preview the recorded presentations 24 hours before the scheduled start time, to facilitate submission of questions to the live panels.  All registered attendees will be able to access the content for 6 months after the event.

KEY TOPICS

The last 18 months have again seen momentous change in the US tobacco control and legal and regulatory landscape. The tragic EVALI outbreak, which in the minds of many still appears to have been related to nicotine-containing e-cigarettes triggered a wave of hostile government action and tobacco control activism directed at the e-cigarette industry. The EVALI crisis developed concurrently with the release of the 2019 NYTS data, which reflected another dramatic rise in past 30-day e-cigarette use by both high school and middle school youth. Both events appeared to play a role in the former president Trump September 2019 announcement of a decision to remove all flavored e-cigarette products from the marketplace. Though that announcement was partially moderated in FDA’s early 2020 guidance that directed the removal of flavored “cartridge based” products only, there is increased uncertainty around the future of flavored e-cigarettes in the U.S. Now, all U.S. e-cigarette products have been required to enter the premarket tobacco product application (PMTA) process with the FDA – a process that could lead to the removal from the market of a significant number of current products, while potentially answering critical questions regarding product safety and the role of flavors for those products that are able to successfully obtain a PMTA.

As we look ahead to the next 12 months, it remains to be seen how the long-awaited PMTA deadline will impact the potential of tobacco harm reduction (THR). Critical questions include whether FDA product review will provide a measure of stability of this brand new category and whether it will improve the tenor of the U.S. tobacco control conversation. The 2020 NYTS numbers will be examined closely and could again significantly impact legal and regulatory policymaking. This year’s E-Cigarette Summit USA comes on the eve of a historical transition for the US e-cigarette industry and under the shadow of the Covid pandemic – where socio economic health disparities have been bought in to sharp focus.  As always, the Summit looks to provide an evidence based environment that encourages open and respectful dialogue on the key science and current public health topics, with a single aim of reducing smoking related death and disease.

  • Tobacco Control, Harm Reduction and Science – Maintaining integrity
  • What are the likely impacts of the PMTA and new regulations
  • Latest youth and adult data
  • The emerging interaction between cannabis, vaping and smoking in young people
  • What lessons can be learned from the tragic EVALI cases
  • “Devaluing” combusted products and the continuum of risk for nicotine containing products
  • How can we reach a sustainable consensus on tobacco harm reduction and tobacco control
  • Has protecting youth overshadowed the opportunity to help smokers
  • PMTA and MRTP regulation – what this will mean for public health, industry and consumers
  • U.S. Tobacco Control Lessons Learned from the Intersection of Wall Street and Washington

SPEAKERS

Dr. Jasjit S. Ahluwalia

Professor, Behavioural and Social Sciences & Internal Medicine

Brown University, School of Public Health & Alpert School of Medicine

Deborah Arnott

Chief Executive

Action on Smoking and Health (UK)

Clive Bates

Director

Counterfactual Consulting Ltd

Kathleen Crosby

Director, Office of Health Communication & Education

FDA Center for Tobacco Products

Prof Mike Cummings

Professor, Dep't Psychiatry & Behavioural Sciences

Medical University of South Carolina

Cliff Douglas, JD

Director, Tobacco Research Network, Adjunct Professor, Department of Health Management and Policy

School of Public Health, University of Michigan

Abigail Friedman

Assistant Professor

Dept of Health Policy & Management, Yale School of Public Health

David Graham

Chief Impact Officer

NJOY

Jamie Hartmann-Boyce

Senior Research Fellow and Editor, Cochrane Tobacco Addiction Group

Nuffield Department of Primary Care Health Sciences, University of Oxford

Dr Cheryl Healton DrPH

Dean and Professor of Public Health Policy and Management

School of Global Public Health, New York University

Matthew R. Holman

Director, Office of Science (OS),Center for Tobacco Products (CTP)

U.S. Food and Drug Administration

Prof Thomas J. Glynn, PhD

Adjunct Lecturer

Stanford Prevention Research Centre, Stanford University School of Medicine

Jaron King

Surveillance Co-ordinator

South Carolina Division of Tobacco Prevention and Control

Prof Scott Leischow

Professor, College of Health Solutions

Arizona State University

Prof David Levy

Professor of Oncology

Lombardl Comprehensive Cancer Center, Georgetown University

Professor Ann McNeill

Professor of Tobacco Addiction

Institute of Psychiatry, Psychology & Neuroscience,, Kings College London

Dr Robin Mermelstein

Professor of Psychology and IHRP Director

University of Illinois, Chicago

Prof Richard Miech

Principal Investigator, Monitoring the Future

Institute for Social Research, University of Michigan

Stefanie Miller

Managing Director

FiscalNote Markets

Ethan Nadelmann

Founder

Drug Policy Alliance

Prof Neal L. Benowitz

Professor of Medicine and Bioengineering & Theapeutic Sciences

University of California, San Franciso

Dr Ray Niaura

Professor of Social & Behavioural Health & Co-Director of the Tobacco Research Lab

School of Global Public Health, New York University

Asst. Prof Jennifer Pearson

Assistant Professor in Health Administration and Policy, School of Community Health Sciences

University of Nevada, Reno School of Community Health Sciences

Dr Michael Pesko

Associate Professor, Dep't of Economics

Andrew Young School of Policy Studies, Georgia State University

Tim Phillips

Managing Director

ECigIntelligence

Dr. Nancy A. Rigotti, MD

Professor of Medicine, Harvard Medical School

Director, Tobacco Research & Treatment Center, Massachusetts General Hospital, Boston

Prof Scott Sherman

Professor of Population Health, Medicine and Psychiatry

NYU Grossman School of Medicine

Ruoyan Sun

Assistant Professor

Dep't of Health Care Organization & Policy, School of Public Health,University of Alabama at Birmingham

Prof Kenneth Warner

Professor Emeritus and Dean Emeritus

School of Public Health, University of Michigan

Dr Alex Wodak

President

Australian Drug Law Reform

Ben Youdan

Director

Youdan Consulting - New Zealand